LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article ; Online: Efficient Production of a Thermostable Mutant of Transglutaminase by

    Ye, Jiacai / Yang, Penghui / Zhou, Jingwen / Du, Guocheng / Liu, Song

    Journal of agricultural and food chemistry

    2024  Volume 72, Issue 8, Page(s) 4207–4216

    Abstract: The transglutaminase (TGase) ... ...

    Abstract The transglutaminase (TGase) from
    MeSH term(s) Transglutaminases/genetics ; Transglutaminases/metabolism ; Streptomyces/metabolism ; Bacterial Proteins/metabolism
    Chemical Substances Transglutaminases (EC 2.3.2.13) ; Bacterial Proteins
    Language English
    Publishing date 2024-02-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 241619-0
    ISSN 1520-5118 ; 0021-8561
    ISSN (online) 1520-5118
    ISSN 0021-8561
    DOI 10.1021/acs.jafc.3c07621
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Enhanced Thermostability and Catalytic Activity of

    Yang, Penghui / Wang, Xinglong / Ye, Jiacai / Rao, Shengqi / Zhou, Jingwen / Du, Guocheng / Liu, Song

    Journal of agricultural and food chemistry

    2023  Volume 71, Issue 16, Page(s) 6366–6375

    Abstract: Streptomyces ... ...

    Abstract Streptomyces mobaraenesis
    MeSH term(s) Enzyme Stability ; Streptomyces/genetics ; Streptomyces/metabolism ; Transglutaminases/chemistry ; Proteins ; Molecular Dynamics Simulation ; Temperature
    Chemical Substances Transglutaminases (EC 2.3.2.13) ; Proteins
    Language English
    Publishing date 2023-04-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 241619-0
    ISSN 1520-5118 ; 0021-8561
    ISSN (online) 1520-5118
    ISSN 0021-8561
    DOI 10.1021/acs.jafc.3c00260
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Endocannabinoid System Unlocks the Puzzle of Autism Treatment

    Su, Tangfeng / Yan, Yu / Li, Qiang / Ye, Jiacai / Pei, Lei

    Frontiers in psychiatry

    2021  Volume 12, Page(s) 734837

    Abstract: Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder and characterized by early childhood-onset impairments in social interaction and communication, restricted and repetitive patterns of behavior or interests. So far there is no ... ...

    Abstract Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder and characterized by early childhood-onset impairments in social interaction and communication, restricted and repetitive patterns of behavior or interests. So far there is no effective treatment for ASD, and the pathogenesis of ASD remains unclear. Genetic and epigenetic factors have been considered to be the main cause of ASD. It is known that endocannabinoid and its receptors are widely distributed in the central nervous system, and provide a positive and irreversible change toward a more physiological neurodevelopment. Recently, the endocannabinoid system (ECS) has been found to participate in the regulation of social reward behavior, which has attracted considerable attention from neuroscientists and neurologists. Both animal models and clinical studies have shown that the ECS is a potential target for the treatment of autism, but the mechanism is still unknown. In the brain, microglia express a complete ECS signaling system. Studies also have shown that modulating ECS signaling can regulate the functions of microglia. By comprehensively reviewing previous studies and combining with our recent work, this review addresses the effects of targeting ECS on microglia, and how this can contribute to maintain the positivity of the central nervous system, and thus improve the symptoms of autism. This will provide insights for revealing the mechanism and developing new treatment strategies for autism.
    Language English
    Publishing date 2021-10-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2021.734837
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Prognostic value of CD247 in patients with head and neck squamous cell carcinoma: bioinformatic analysis of TCGA database.

    Lin, Peng / Hu, Xiao-Li / Hu, Yuan-Yuan / Liu, Mai-Ying / Wang, Qian-Yu / Ding, Yan / Ye, Jia-Cai

    Annals of translational medicine

    2022  Volume 10, Issue 17, Page(s) 923

    Abstract: Background: Head and neck squamous cell carcinoma (HNSC) is the 7th most common type of cancer in the world. Through the advantages of The Cancer Genome Atlas (TCGA) large-scale sequencing-based genome analysis technology, we can explore the potential ... ...

    Abstract Background: Head and neck squamous cell carcinoma (HNSC) is the 7th most common type of cancer in the world. Through the advantages of The Cancer Genome Atlas (TCGA) large-scale sequencing-based genome analysis technology, we can explore the potential molecular mechanisms that can improve the prognosis of HNSC patients.
    Methods: The HNSC transcriptome and clinical data were downloaded from TCGA database. A univariate survival analysis and differential expression analysis were conducted to obtain the intersection gene set. A protein-protein interaction (PPI) analysis, modular analysis, and Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis were then conducted to identify the hub genes. Clinical correlation analysis, univariate and multivariate Cox regression analyses were performed on the identified hub genes to determine the prognostic impact of hub genes on HNSC patients.
    Results: In total, 601 intersecting gene sets were obtained. A modular analysis was conducted, and the highest scoring module was 19.304. Based on the GO/KEGG enrichment analysis results, CD247 molecule (CD247) was ultimately selected as the gene for this study. The CD247 were divided into a high-expression group and a low-expression group. The Kaplan-Meier survival curve analysis showed that there was a significant difference between the 2 groups (P<0.0001). The median survival time of the low-expression CD247 group was 30.9 months, and the 5-year survival rate was 36.4%. While the median survival time of the high-expression CD247 group was 68.8 months, and the 5-year survival rate was 52.3%. The clinical correlation analysis showed that CD247 was significantly negatively correlated with pathological tumor stage (pT) and pathological nodal extracapsular spread. Gene Set Enrichment Analysis (GSEA) showed that CD247 activating KEGG pathway hsa04650 and hsa04660.
    Conclusions: CD247 is an independent protective factor in the prognosis of HNSC patients. By activating the hsa04650 and hsa04660 pathways, the expression of interferon gamma, interleukin (IL)-2, and IL-10 is promoted, which in turn improves the tumor immune monitoring ability of the body, induces tumor cell apoptosis, and inhibits tumor cell growth. CD247 is a potential target for improving the clinical treatment effect of HNSC and the prognosis of patients.
    Language English
    Publishing date 2022-09-22
    Publishing country China
    Document type Journal Article
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm-22-1143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators.

    Zhang, Jian / Jiang, Huali / Du, Kunpeng / Xie, Tao / Wang, Baiyao / Chen, Chengcong / Cen, Bohong / Yuan, Yawei / Ye, Jiacai

    Frontiers in medicine

    2021  Volume 8, Page(s) 662460

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2021-08-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2021.662460
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: MicroRNA-124-3p

    Ye, Jiacai / Liao, Quanxing / Zeng, Xiaohui / Liu, Chang / Ding, Yan / Liu, Xuefeng / Zeng, Lisi / Guan, Tianpei / Yuan, Yawei

    Journal of Cancer

    2021  Volume 12, Issue 16, Page(s) 4933–4944

    Abstract: Nasopharyngeal carcinoma (NPC) is characterised by distinct geographical distribution and is particularly prevalent in Asian countries. But the mechanisms related to the progression of nasopharyngeal carcinoma (NPC) are not completely understood. MiR-124- ...

    Abstract Nasopharyngeal carcinoma (NPC) is characterised by distinct geographical distribution and is particularly prevalent in Asian countries. But the mechanisms related to the progression of nasopharyngeal carcinoma (NPC) are not completely understood. MiR-124-3p functions as a tumor suppressor in many kinds of human cancers. Here, we explored the effects and mechanism of
    Language English
    Publishing date 2021-06-11
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 2573318-7
    ISSN 1837-9664
    ISSN 1837-9664
    DOI 10.7150/jca.57152
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Noncoding RNAs and hyperthermic intraperitoneal chemotherapy in advanced gastric cancer.

    Zeng, Lisi / Liao, Quanxing / Zeng, Xiaohui / Ye, Jiacai / Yang, Xianzi / Zhu, Siyu / Tang, Hongsheng / Liu, Gaojie / Cui, Weiwen / Ma, Shaohua / Cui, Shuzhong

    Bioengineered

    2022  Volume 13, Issue 2, Page(s) 2623–2638

    Abstract: Gastric cancer (GC) is one of the most common malignant tumors globally. About 20-30% of patients with gastric cancer show peritoneal implantation metastasis at the first diagnosis. Peritoneal metastasis is responsible for 70% of deaths of patients with ... ...

    Abstract Gastric cancer (GC) is one of the most common malignant tumors globally. About 20-30% of patients with gastric cancer show peritoneal implantation metastasis at the first diagnosis. Peritoneal metastasis is responsible for 70% of deaths of patients with advanced gastric cancer. Although there are many ways to treat advanced gastric cancer, the prognosis of patients with recurrence is unsatisfactory. An auxiliary treatment with hyperthermic intraperitoneal chemotherapy (HIPEC), is an internationally recognized recommended treatment for advanced gastric cancer. A series of clinical trials have shown that HIPEC significantly improves the overall survival of patients with cancer. Compared with the cytoreductive surgery (CRS) alone, HIPEC combined with CRS markedly reduced the rate of peritoneal metastasis in patients with ovarian cancer and colorectal cancer. It has been demonstrated that HIPEC alters transcription of many genes by affecting non-coding RNAs, which may contribute to the suppressive effect of HIPEC on the synthesis of nucleic acids and proteins in cancer cells. This paper reviews the recent advances in understanding the role of non-coding RNAs in tumor invasion and metastasis of advanced gastric cancer. We also consider changes in noncoding RNA levels and other molecules in advanced gastric cancer cases treated with HIPEC. We hope that our review will provide a reference for future research on molecular epidemiology and etiology of advanced gastric cancer and promote precise treatment of this malignancy using HIPEC.
    MeSH term(s) Cytoreduction Surgical Procedures ; Humans ; Hyperthermic Intraperitoneal Chemotherapy ; RNA, Neoplasm/metabolism ; RNA, Untranslated/genetics ; RNA, Untranslated/metabolism ; Stomach Neoplasms/genetics ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/mortality ; Stomach Neoplasms/therapy ; Survival Rate
    Chemical Substances RNA, Neoplasm ; RNA, Untranslated
    Language English
    Publishing date 2022-01-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Video-Audio Media
    ZDB-ID 2737830-5
    ISSN 2165-5987 ; 2165-5979
    ISSN (online) 2165-5987
    ISSN 2165-5979
    DOI 10.1080/21655979.2021.2021348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Prognostic impact of pretreatment serum superoxide dismutase activity in patients with locoregionally advanced nasopharyngeal carcinoma.

    Qiu, Wenze / Jiang, Jiali / Zhan, Zejiang / Huang, Laiji / Deng, Jin / Ye, Jiacai / Li, Guo / Liao, Kai / Zhang, Huanhuan / Ding, Yan / Yuan, Yawei / Zheng, Ronghui

    The International journal of biological markers

    2022  Volume 37, Issue 1, Page(s) 21–30

    Abstract: Purpose: To evaluate the prognostic effect of pretreatment serum superoxide dismutase (SOD) activity in locoregionally advanced nasopharyngeal carcinoma.: Methods: A total of 498 patients diagnosed with stage III-IVA nasopharyngeal carcinoma between ... ...

    Abstract Purpose: To evaluate the prognostic effect of pretreatment serum superoxide dismutase (SOD) activity in locoregionally advanced nasopharyngeal carcinoma.
    Methods: A total of 498 patients diagnosed with stage III-IVA nasopharyngeal carcinoma between January 2013 and December 2016 were involved in this study. The X-tile program was used to determine the cut-off value of pretreatment serum SOD activity based on disease-free survival. Kaplan-Meier methods and Cox proportional hazards models were used to evaluate the impact of serum SOD levels on survival outcomes. The receiver operating characteristic (ROC) curve analysis was used to compare the prognostic value of clinical stage, pretreatment serum SOD level, and the combination of them regarding disease-free survival.
    Results: Based on the X-tile plot, the optimal cutoff value of pretreatment serum SOD activity for disease-free survival was 146.0U/mL. As a dichotomous variable, SOD was significantly higher in non-keratinizing differentiated disease (
    Conclusion: Serological SOD activity before treatment is an important prognostic indicator for patients with stage III-IV non-metastatic nasopharyngeal carcinoma undergoing chemoradiation therapy.
    MeSH term(s) Disease-Free Survival ; Humans ; Kaplan-Meier Estimate ; Nasopharyngeal Carcinoma/pathology ; Nasopharyngeal Neoplasms/pathology ; Nasopharyngeal Neoplasms/therapy ; Neoplasm Staging ; Prognosis ; Superoxide Dismutase
    Chemical Substances Superoxide Dismutase (EC 1.15.1.1)
    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645113-5
    ISSN 1724-6008 ; 0393-6155
    ISSN (online) 1724-6008
    ISSN 0393-6155
    DOI 10.1177/17246008221075042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma.

    Zhang, Huan-Huan / Yuan, Tai-Ze / Li, Jian / Liang, Yin / Huang, Lai-Ji / Ye, Jia-Cai / Zheng, Rong-Hui / Xie, Guo-Feng / Zhang, Xiu-Ping

    Experimental and therapeutic medicine

    2013  Volume 6, Issue 4, Page(s) 1062–1066

    Abstract: The aim of this study was to explore the effects of erlotinib combined with radiation on human nasopharyngeal carcinoma (NPC) radiosensitivity using the CNE1 and CNE2 cell lines. Human NPC cells were treated with erlotinib and/or radiation. The effect of ...

    Abstract The aim of this study was to explore the effects of erlotinib combined with radiation on human nasopharyngeal carcinoma (NPC) radiosensitivity using the CNE1 and CNE2 cell lines. Human NPC cells were treated with erlotinib and/or radiation. The effect of erlotinib on the radiosensitivity of the cells was detected using a clonogenic cell survival assay. The rate of apoptosis and the cell cycle were evaluated using flow cytometry. An NPC xenograft model in NOD-SCID mice was used to evaluate the efficacy of the combination therapy of erlotinib with radiation. Erlotinib enhanced the sensitivity of the CNE1 and CNE2 cells to radiation, with sensitization enhancement ratios (SERs) of 1.076 and 1.109, respectively. Erlotinib combined with radiation induced G2/M phase cell cycle arrest in the two cell lines. The mouse tumor model demonstrated a significant reduction in NPC tumor volume in mice treated with erlotinib in combination with radiation when compared with that in mice treated with radiation alone. Erlotinib combined with radiation provoked G2-M phase cell cycle arrest, thereby enhancing the sensitivity of the NPC cells to radiation.
    Language English
    Publishing date 2013-08-02
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2683844-8
    ISSN 1792-1015 ; 1792-0981
    ISSN (online) 1792-1015
    ISSN 1792-0981
    DOI 10.3892/etm.2013.1245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top